Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

Classification of Illness

Classification of Illness

The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).

HemaSphere·2022

Same author

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.

Cancer chemotherapy and pharmacology·2019

Same author

Revue medicale suisse·2018

Same author

Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.

Clinical genitourinary cancer·2017

Same author

Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).

Leukemia & lymphoma·2010

Same author

Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95.

Leukemia & lymphoma·2009

Search research articles

Related Experiment Video

Updated: May 12, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

[Indolent lymphomas: classification, clinical presentation and treatment]].

Reinhard Zenhäusern¹

¹Abteilung Onkologie-Hämatologie, Spitalzentrum Oberwallis, Brig. reinhard.zenhaeusern@hospitals.ch

|March 28, 2013

Summary

Malignant lymphomas are diverse lymphatic system cancers. Current antibody therapies improve prognosis for indolent lymphomas, but cures remain elusive, prioritizing quality of life.

Area of Science:

Hematology
Oncology
Immunology

Context:

Malignant lymphomas represent a complex group of lymphatic system neoplasms.
The World Health Organization (WHO) classification delineates 70 distinct lymphoma entities.
Each lymphoma subtype possesses unique clinical, morphological, immunophenotypic, and genetic features.

Purpose:

To review current treatment strategies for indolent lymphomas.
To discuss the role of antibody-based therapies and their impact on prognosis.
To highlight the importance of maintaining quality of life and avoiding treatment toxicities.

Summary:

Indolent lymphomas, including follicular lymphoma and chronic lymphocytic leukemia, are characterized by slow progression.
While antibody-based treatments have enhanced patient outcomes, curative options are limited.

Related Experiment Videos

Last Updated: May 12, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

The 'watch and wait' approach remains a viable strategy for asymptomatic patients.

Impact:

Improved understanding of indolent lymphoma management.
Guidance on optimizing therapeutic goals towards quality of life and reduced toxicity.
Informed clinical decision-making for patients with indolent lymphomas.